Compare NFGC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NFGC | SLN |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.6M | 678.0M |
| IPO Year | 2021 | 2010 |
| Metric | NFGC | SLN |
|---|---|---|
| Price | $1.57 | $9.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $4.26 | ★ $33.00 |
| AVG Volume (30 Days) | 782.7K | ★ 885.1K |
| Earning Date | 08-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $559,000.00 |
| Revenue This Year | $994.66 | N/A |
| Revenue Next Year | $230.05 | $132.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.34 | $4.19 |
| 52 Week High | $3.59 | $17.58 |
| Indicator | NFGC | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 41.21 | 30.63 |
| Support Level | $1.45 | $4.70 |
| Resistance Level | $1.60 | $11.06 |
| Average True Range (ATR) | 0.07 | 0.58 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 17.11 | 26.27 |
New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Companies exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.